Randomized phase III trial compared cisplatin and irinotecan (CPT-P) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC) — The final report

Komiya, Takefumi; Fukuoka, Masahiro; Negoro, Shunichi; Masuda, Noriyuki; Takada, Yoshiki; Sugiura, T; Ōhashi, Y.; Niitani, Hisanobu

doi:10.1016/s0169-5002(00)80088-4

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20][21][22][23][24][25] The combination of CPT-11 and cisplatin represents the standard of care in Japan based on Phase III trials conducted in that country. 26,27 We have previously reported a Phase I trial that combined escalating doses of CPT-11 with fixed doses of carboplatin and paclitaxel in 33 patients with advanced NSCLC. 28 The primary DLT of this regimen was diarrhea and neutropenia.…”

mentioning

confidence: 99%

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

Socinski

Sandler

Israel

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDThis Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC).METHODSPatients received repeated 21‐day cycles at starting doses of paclitaxel 175 mg/m2 administered over 3 hours, followed by carboplatin AUC of 5 over 30 minutes and CPT‐11 at a starting dose level of 100 mg/m2 over 90 minutes, all given on the first day of each cycle. Patients were evaluated for objective tumor response, time to tumor progression (TTP), survival, and safety.RESULTSForty patients were enrolled. Baseline patient characteristics included: median age 58 years (range, 32–79); 23 males and 17 females; performance status of 0 (21 patients), 1 (18 patients), or 2 (1 patient); and Stage IIIB (10 patients) and Stage IV (30 patients) disease. A median of six cycles (range, one to eight) were administered. Grade 3–4 toxicities observed in ≥ 10% of the patients included neutropenia (78%), asthenia (20%), diarrhea (20%), nausea (18%), vomiting (13%), anemia (10%), and dyspnea (10%). Febrile neutropenia occurred in eight patients (20%), with one death due to neutropenic sepsis. Twelve of 38 evaluable patients had confirmed tumor responses (32%), while 21 (55%) had stable disease (including 12 patients [32%] with minor responses). Only 13% had disease progression at their initial tumor assessment. The median TTP and survival were 5.3 months (range, 0.03–6.2 months) and 12.5 months (range 0.3–28.6+ months), respectively. The one and two year survival probabilities were 0.50 (95% confidence interval [CI], 0.28–0.73) and 0.21 (95% CI, 0.0–0.67), respectively.CONCLUSIONSThe combination of CPT‐11, paclitaxel, and carboplatin can be safely administered and is active in the treatment of advanced NSCLC. Based on the favorable survival outcome, this regimen is undergoing evaluation in prospective randomized trials. Cancer 2002;95:1520–7. © 2002 American Cancer Society.DOI 10.1002/cncr.10852

show abstract